Collplant Biotechnologies

Collplant Biotechnologies EBIT Margin

The EBIT Margin (Operating Margin) of Collplant Biotechnologies (CLGN) as of Nov 2, 2026 is -484.31 %. In the previous year, EBIT Margin (Operating Margin) was -3,349.71 % — a change of -85.54% (higher).

EBIT Margin

-484.31 %

YoY

-85.54%

Last updated:

EBIT Margin (Operating Margin) of Collplant Biotechnologies is 2025 -484.31 % . EBIT Margin (Operating Margin) of Collplant Biotechnologies was 2024 -3,349.71 % . It decreases by -85.54% higher compared to the previous year.

For Collplant Biotechnologies, the operating (EBIT) margin of -484.3% is down versus 0.4% a few years ago.

The Collplant Biotechnologies EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-84.91 USD
Jan 1, 2019
-329.21 USD
Jan 1, 2020
-91.23 USD
Jan 1, 2021
0.42 USD
Jan 1, 2022
-5,718.06 USD
Jan 1, 2023
-68.55 USD
Jan 1, 2024
-3,349.71 USD
Jan 1, 2025
-484.31 USD
The Collplant Biotechnologies EBIT Margin history
YEAREBIT MarginYoY
-484.31 %-85.54%
-3,349.71 %+4,786.78%
-68.55 %-98.80%
-5,718.06 %-1.38 M%
0.42 %-100.46%
-91.23 %-72.29%
-329.21 %+287.73%
-84.91 %-93.18%
-1,244.19 %-86.81%
-9,433.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Collplant Biotechnologies Stock analysis

What does Collplant Biotechnologies do? CollPlant Biotechnologies Ltd. develops and markets regenerative medicine products based on plant-derived collagen type I (rhCollagen) for tissue repair and organ bioprinting. The company focuses on medical aesthetics and tissue regeneration applications, targeting healthcare providers and research institutions seeking advanced bioprinting solutions. Its core technology enables the production of collagen without animal sources, addressing market demands for ethical and sustainable biomaterials. The firm's products include bioprinting solutions for tissue and organ production, which are sold to medical research organizations and healthcare facilities. CollPlant's technology differentiates itself through plant-based collagen, appealing to clients prioritizing eco-friendly and animal-free medical solutions. This approach aligns with growing industry trends toward sustainable regenerative medicine practices. CollPlant Biotechnologies Ltd. generates revenue through the sale of its bioprinting technologies and collagen-based medical products. The company's target segments include regenerative medicine researchers, tissue engineering specialists, and medical aesthetics providers who require advanced biomaterials for their applications. These segments value the company's plant-derived collagen technology for its ethical sourcing and performance in tissue repair applications. Collplant Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Collplant Biotechnologies stock

EBIT Margin (Operating Margin) of Collplant Biotechnologies is -484.31 % in 2025.

EBIT Margin (Operating Margin) of Collplant Biotechnologies changed from -3,349.71 % to -484.31 %, representing a -85.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Collplant Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Collplant Biotechnologies with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Collplant Biotechnologies

All Key Metrics — Collplant Biotechnologies